Business Standard

Sunday, December 22, 2024 | 07:26 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Serum Institute tops profit charts among unlisted firms amid Covid war

Surge in demand for Covishield led to a huge spike in its revenues and profits

Serum Institute
Premium

Serum Institute

Krishna Kant Mumbai
Pandemic-led changes in the global and domestic economy have yielded big gains for corporations across many sectors.

Pune-based vaccine maker Serum Institute of India (SII) seems to be one of the biggest gainers among them. The global surge in demand for its Covishield vaccine, a prophylactic for Covid-19, led to a big spike in SII’s revenues and profits in the last two years.

The company’s revenues more than tripled in FY22 over the previous year and it became the most profitable unlisted company and the most profitable pharma maker in the country by a big margin.

The company’s net profit

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in